Cargando…

Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks

OBJECTIVES: This study aims to quantitatively assess the profile of the choroidal thickness (ChT) in patients with ankylosing spondylitis (AS) using optical coherence tomography (OCT), and to examine whether the posterior eye segment abnormalities in active AS patients are reversible by infliximab t...

Descripción completa

Detalles Bibliográficos
Autores principales: KARKUCAK, Murat, KOLA, Mehmet, KALKIŞIM, Ahmet, ÇAPKIN, Erhan, AYAR, Ahmet, TÜRK, Adem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish League Against Rheumatism 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140873/
https://www.ncbi.nlm.nih.gov/pubmed/34046569
http://dx.doi.org/10.46497/ArchRheumatol.2021.7806
_version_ 1783696263955349504
author KARKUCAK, Murat
KOLA, Mehmet
KALKIŞIM, Ahmet
ÇAPKIN, Erhan
AYAR, Ahmet
TÜRK, Adem
author_facet KARKUCAK, Murat
KOLA, Mehmet
KALKIŞIM, Ahmet
ÇAPKIN, Erhan
AYAR, Ahmet
TÜRK, Adem
author_sort KARKUCAK, Murat
collection PubMed
description OBJECTIVES: This study aims to quantitatively assess the profile of the choroidal thickness (ChT) in patients with ankylosing spondylitis (AS) using optical coherence tomography (OCT), and to examine whether the posterior eye segment abnormalities in active AS patients are reversible by infliximab therapy. PATIENTS AND METHODS: October 2014 and March 2016 Thirty-one patients with AS (22 males, 9 females; mean age 39.6±12.3 years; range, 22 to 68 years) and 24 healthy controls (16 males, 8 females; mean age 40.8±8.9 years; range, 35 to 61 years) were enrolled. Patients’ clinical and demographic characteristics were recorded. Using OCT, we performed retinal nerve fiber layer (RNFL) thickness, ganglion cell complex, and ChT measurements in AS patients before and six months after the initiation of infliximab therapy, and in healthy controls. RESULTS: At baseline, patients with AS had higher ChT (mean±standard deviation: 347.5±114.4 μm) compared to healthy controls (322.1±62.8 μm), although this did not reach statistical significance level (p=0.283). At six months after the first measurement, the mean ChT was significantly decreased (under infliximab therapy: 326.5±99.7 μm vs. before: 347.5±114.4 μm, p=0.018) in AS group, while no significant change was observed in the control group (p=0.102). RNFL thickness in the AS group was significantly decreased after six months of treatment with infliximab (p=0.008). CONCLUSION: By evaluating the posterior eye segment of patients with AS using OCT, this study has demonstrated that active AS patients had higher ChT. The significant reduction in this ChT after infliximab therapy may be mediating the established effective suppressing action of infliximab on uveitis attacks.
format Online
Article
Text
id pubmed-8140873
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Turkish League Against Rheumatism
record_format MEDLINE/PubMed
spelling pubmed-81408732021-05-26 Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks KARKUCAK, Murat KOLA, Mehmet KALKIŞIM, Ahmet ÇAPKIN, Erhan AYAR, Ahmet TÜRK, Adem Arch Rheumatol Original Article OBJECTIVES: This study aims to quantitatively assess the profile of the choroidal thickness (ChT) in patients with ankylosing spondylitis (AS) using optical coherence tomography (OCT), and to examine whether the posterior eye segment abnormalities in active AS patients are reversible by infliximab therapy. PATIENTS AND METHODS: October 2014 and March 2016 Thirty-one patients with AS (22 males, 9 females; mean age 39.6±12.3 years; range, 22 to 68 years) and 24 healthy controls (16 males, 8 females; mean age 40.8±8.9 years; range, 35 to 61 years) were enrolled. Patients’ clinical and demographic characteristics were recorded. Using OCT, we performed retinal nerve fiber layer (RNFL) thickness, ganglion cell complex, and ChT measurements in AS patients before and six months after the initiation of infliximab therapy, and in healthy controls. RESULTS: At baseline, patients with AS had higher ChT (mean±standard deviation: 347.5±114.4 μm) compared to healthy controls (322.1±62.8 μm), although this did not reach statistical significance level (p=0.283). At six months after the first measurement, the mean ChT was significantly decreased (under infliximab therapy: 326.5±99.7 μm vs. before: 347.5±114.4 μm, p=0.018) in AS group, while no significant change was observed in the control group (p=0.102). RNFL thickness in the AS group was significantly decreased after six months of treatment with infliximab (p=0.008). CONCLUSION: By evaluating the posterior eye segment of patients with AS using OCT, this study has demonstrated that active AS patients had higher ChT. The significant reduction in this ChT after infliximab therapy may be mediating the established effective suppressing action of infliximab on uveitis attacks. Turkish League Against Rheumatism 2020-09-04 /pmc/articles/PMC8140873/ /pubmed/34046569 http://dx.doi.org/10.46497/ArchRheumatol.2021.7806 Text en Copyright © 2020, Turkish League Against Rheumatism https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Article
KARKUCAK, Murat
KOLA, Mehmet
KALKIŞIM, Ahmet
ÇAPKIN, Erhan
AYAR, Ahmet
TÜRK, Adem
Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks
title Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks
title_full Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks
title_fullStr Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks
title_full_unstemmed Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks
title_short Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks
title_sort infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: a possible mechanism mediating the suppressing of uveitis attacks
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140873/
https://www.ncbi.nlm.nih.gov/pubmed/34046569
http://dx.doi.org/10.46497/ArchRheumatol.2021.7806
work_keys_str_mv AT karkucakmurat infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks
AT kolamehmet infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks
AT kalkisimahmet infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks
AT capkinerhan infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks
AT ayarahmet infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks
AT turkadem infliximabtherapyprovidesbeneficialeffectsforchoroidalthicknessincreaseinpatientswithactiveankylosingspondylitisapossiblemechanismmediatingthesuppressingofuveitisattacks